Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 4Plasma cell 1Other hematologic neoplasm 1CNS 1

Conditions

Multiple Myeloma 873Neoplasms, Plasma Cell 162Lymphoma, Non-Hodgkin 139Lymphoma 135Hodgkin Disease 134Leukemia, Lymphocytic, Chronic, B-Cell 118Precursor Cell Lymphoblastic Leukemia-Lymphoma 109Myelodysplastic Syndromes 103Recurrence 101Leukemia, Myeloid, Acute 99Leukemia 94Lymphoma, Mantle-Cell 80Lymphoma, Large B-Cell, Diffuse 76Lymphoma, Follicular 73Myeloproliferative Disorders 69Lymphoma, B-Cell, Marginal Zone 69Hematologic Neoplasms 64Burkitt Lymphoma 64Primary Myelofibrosis 57Lymphoma, Large-Cell, Immunoblastic 55Waldenstrom Macroglobulinemia 52Leukemia, Myelogenous, Chronic, BCR-ABL Positive 52Leukemia, Myeloid, Chronic-Phase 46Lymphoma, T-Cell, Cutaneous 44Immunoglobulin Light-chain Amyloidosis 43Congenital Abnormalities 43Neoplasms 41Leukemia, Myelomonocytic, Chronic 41Leukemia, Myeloid, Accelerated Phase 40Sezary Syndrome 38

Interventions

siltuximab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Cytokine Release Syndrome × Plasma cell × Clear all
NCT04975555 2026-06-03

Study to Evaluate the Role of Siltuximab in Treatment of Cytokine Release Syndrome (CRS) and Immune Effector Cell Associated Neurotoxicity (ICANS) Related to CAR-T Cell Therapy

University of Alabama at Birmingham

Phase 2 Completed
24 enrolled 8 charts
LymphoidOther hematologic neoplasmPlasma cell

Cytokine Release Syndrome, Lymphoma, Lymphoma, Non-Hodgkin, Multiple Myeloma, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡